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Humoral Response Following Transcatheter Aortic Valve Replacement Comparing
Transapical and Transfemoral Approaches
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Pendyala K. Lakshmana, Joshua P. Loh, Hideaki Ota, Al Fazir Omar,
Jose F. Rodriguez-Weisson, Rebecca Torguson, Petros G. Okubagzi, Fang Chen,
William O. Suddath, Itsik Ben-Dor, Lowell F. Satler, Augusto Pichard, Ron Waksman
MedStar Heart Institute, Washington, DC
Background: High serum brain natriuretic peptide (BNP) (>400 pg/ml) is associated
with high morbidity and mortality following Transcatheter Aortic Valve Replacement
(TAVR). However, whether TA is associated with a distinct humoral response pattern
has not been established.
Methods: We compared the BNP distribution (median and IQR) at baseline and at
hospital discharge following TAVR stratiﬁed according into those who underwent
transapical (TA) or transfemoral (TF) approach.
Results: A total of 217 patients underwent TAVR for symptomatic aortic stenosis. The
mean age was 84  7 years-old and 27% (n¼60) underwent TA approach. The preva-
lence of left ventricular ejection fraction (LVEF) 40% (27% vs. 20%; p¼0.3), chronic
renal failure (62% vs. 59; p¼0.7) and the baselinemedian BNP levels were comparable in
the TA and TF groups (TA median¼368, [IQR 25th-75th ¼ 205-591]); TF
median¼338 [176-584]; p¼0.6). At discharge, the BNP levels paradoxically increased in
the TA (TAmedian¼ 698 [465-989]) approach as opposed to the TF (TFmedian¼319
[176-584]); p<0.001 (ﬁgure). The echocardiograph correlates for BNP at discharge
were: LVEF (r ¼ -0.49; p<0.01), left ventricular outﬂow tract diameter (r ¼ -0.48;
p<0.03) and the residual aortic mean aortic gradient (r ¼ -0.18; p<0.02).
Conclusion: Patients undergoing TAVR by TA approach have a signiﬁcant increase
in the BNP after the procedure as compared to those who underwent TF. Addi-
tionally, the BNP levels at discharge was negatively correlated to residual aortic valve
gradient, left ventricular outﬂow tract diameter and left ventricular ejection fraction. L
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The Impact of Acute and Chronic Troponin Elevation After Transcatheter Aortic Valve
Implantation
Jan-Malte Sinning, Christoph Hammerstingl, Alexander Ghanem, Fritz Mellert,
Wolfgang Schiller, Mariuca Vasa-Nicotera, Armin Welz, Eberhard Grube, Georg Nickenig,
Nikos Werner
Heart Center Bonn, Bonn, Germany
Background: Myocardial injury deﬁned occurs frequently following transcatheter
aortic valve implantation (TAVR). The aim of this study was to assess timing,predictors, and prognostic value of peri-procedural myocardial injury and chronic
troponin elevation after TAVR.
Methods: 276 patients (logistic EuroSCORE 26.617.1%) underwent transvascular
TAVR. In all patients, troponin I, CK-MB, and NT-proBNP levels were measured
before and after TAVR (1h, 4h, 24h, 48h, 72h, 7 days, 3, and 6 months).
Results: Myocardial injury (according to VARC-2 recommendation deﬁned as
DTrop 15x URL) occurred in 143/276 patients (51.8%) during the ﬁrst 72 hours
following TAVR. Use of a self-expanding prosthesis (p¼0.02), coronary artery disease
(p¼0.04), higher left-ventricular ejection fraction (LVEF) (p<0.001), and procedure
time (p<0.001) were independent predictors for the development of myocardial injury
after TAVR. 30-day (4.2% vs. 6.1%; p¼0.48) and 1-year mortality (19.4% vs. 26.5%;
p¼0.15) were not related to the incidence of peri-procedural myocardial injury.
However, patients with chronic troponin elevation after TAVR had an increased 1-
year mortality risk (HR 4.5, 95%-CI: 2.0-10.0; p<0.001).
Conclusion:Myocardial injury deﬁned as DTrop 15x URL after TAVR seems to be
a procedure-related issue but does not impact survival. However, a post-procedural
troponin increase might be useful for prognostication after TAVR.CRT-708
Initial US Experience with Commercial Transfemoral Edwards SAPIEN Transcatheter
Heart Valve Compared to Partner Cohort B for Inoperable Symptomatic Severe Aortic
Stenosis
Lakshmana Pendyala, Sa’ar Minha, Joshua Loh, Al F. Omar, Rebecca Torguson,
Hideaki Ota, Marco DeMagalhaesPereira, Petros Okubagzi, Ricardo Escarcega Alarcon,
Nevin Baker, Lowell Satler, Augusto Pichard, Ron Waksman
MedStar Heart Institute, Washington, DC
Background: TAVR using the Edwards SAPIEN valve is approved for commercial
use in the United States. This study aims to assess the clinical proﬁle, procedural
characteristics and in-hospital complications in patients treated with a commercial
SAPIEN valve outside the clinical trial context.
Methods: We retrospectively analyzed 69 consecutive inoperable patients who un-
derwent TAVR with a commercial SAPIEN valve compared to 55 PARTNER trial
patients from Cohort B enrolled in the same institution by the same Heart Team.
Results: Compared to the commercial group, patients in the PARTNER Cohort B
had higher mean STS score (105 vs. 94; p¼0.04) and a lower rate of peripheral
arterial disease (19% vs. 44%, p¼0.004). The majority of patients in the commercial
group had the procedure under conscious sedation (83% vs. 66%; p¼0.03). Planned
surgical cut-down for vascular access was rare in the commercial group (1.4% vs. 46%;
p <0.001). The overall rates of major vascular complications, life threatening or major
bleeding and blood transfusions were lower in commercial group (7.2% vs. 27%;
p¼0.003), (2.9% vs. 16%; p¼0.01), and (28% vs. 60%, p <0.001), respectively. In-
hospital all-cause mortality (5.8% vs. 9.1%; p¼0.51) and stroke rates (7.2% vs. 14.5%;
p¼0.19) were statistically not different between the groups. The median length of
hospitalization (p <0.001) and post-procedural length of stay (p¼0.01) was shorter in
the commercial group.
